Research paper
Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study

https://doi.org/10.1016/j.drugpo.2021.103421Get rights and content

Highlights

  • Recent benzodiazepine and hazardous alcohol use is associated with opioid overdose.

  • Naloxone coverage is low among people at risk of overdose.

  • Two thirds of people with recent overdose have never accessed take-home naloxone.

Abstract

Background

Overdose is a major cause of morbidity and mortality among people who use opioids. Naloxone can reverse opioid overdoses and can be distributed and administered with minimal training. People with experience of overdose are a key population to target for overdose prevention strategies. This study aims to understand if factors associated with recent non-fatal opioid overdose are the same as factors associated with naloxone access and naloxone training in people who recently used opioids or received opioid agonist treatment (OAT).

Methods

ETHOS Engage is an observational study of people who inject drugs in Australia. Logistic regression models were used to estimate odds ratios for non-fatal opioid overdose, naloxone access and naloxone training.

Results

Between May 2018-September 2019, 1280 participants who recently used opioids or received OAT were enrolled (62% aged >40 years; 35% female, 80% receiving OAT, 62% injected drugs in the preceding month). Recent opioid overdose (preceding 12 months) was reported by 7% of participants, lifetime naloxone access by 17%, and lifetime naloxone training by 14%. Compared to people receiving OAT with no additional opioid use, recent opioid, benzodiazepine (preceding six months), and hazardous alcohol use was associated with recent opioid overdose (aOR 3.91; 95%CI: 1.68–9.10) and lifetime naloxone access (aOR 2.12; 95%CI 1.29–3.48). Among 91 people who reported recent overdose, 65% had never received take-home naloxone or naloxone training.

Conclusions

Among people recently using opioids or receiving OAT, benzodiazepine and hazardous alcohol use is associated with non-fatal opioid overdose. Not all factors associated with non-fatal overdose correspond to factors associated with naloxone access. Naloxone access and training is low across all groups. Additional interventions are needed to scale up naloxone provision.

Introduction

Globally, in 2017 an estimated 40.5 million people were dependent on opioids (95% CI 34.3–47.9 million) and 109,500 people (95% CI 105,800–113,600) died from opioid overdose (GBD, 2017; Disease & Injury Incidence & Prevalence Collaborators, 2018). There are ∼93,000 people who recently injected drugs in Australia (Degenhardt et al., 2017) and one study estimated non-fatal overdose in the preceding year at 11.9% (Colledge et al., 2019). Non-fatal opioid overdose is a major determinant of morbidity among people who inject drugs (PWID) (Degenhardt et al., 2019; Warner-Smith, Darke, & Day, 2002) and is a predictor of subsequent overdose (Caudarella et al., 2016; Coffin et al., 2007; Forsyth, Carroll, Lennox, & Kinner, 2018). People who have experienced non-fatal overdose are a key population to be targeted for overdose prevention interventions.

Naloxone is a short-acting opioid antagonist which rapidly reverses opioid overdoses, preventing death (Strang et al., 2019). Take-home naloxone programmes train people at risk of overdose (including PWID, people who use illicit opioids, and chronic pain patients receiving opioids) and their peers to administer naloxone in the community setting. Such training programmes successfully increase overdose knowledge and give participants the skills to reverse an overdose (Chronister et al., 2018; Lewis, Vo, & Fishman, 2017; Lintzeris et al., 2020; McAuley, Aucott, & Matheson, 2015; Neale et al., 2019). In Australia, an estimated 30% of PWID at needle syringe programs in urban areas have received training on administering naloxone (Peacock et al., 2019) yet overdose rates are increasing (Man, Chrzanowska, Dobbins, Degenhardt & Peacock, 2019). Since 2016, naloxone has been available in Australian pharmacies over-the-counter to purchase without a prescription or prior training (Lenton, Dietze & Jauncey, 2016). Australian PWID have demonstrated high willingness to obtain take home naloxone from community pharmacies (Lintzeris et al., 2020) but the 2016 change in policy has not resulted in a notable increase in over-the-counter naloxone sales (Tse, Sanfilippo, Lam, Dietze & Nielsen, 2020). Research is needed to determine if naloxone training is reaching people most at risk of overdose.

Studies have identified various sociodemographic and behavioural factors which are associated with overdose; including older age (Kerr et al., 2007; Nechuta, Tyndall, Mukhopadhyay & McPheeters, 2018), younger age (Coffin et al., 2007), homelessness (Kerr et al., 2007; Sherman, Cheng & Kral, 2007), recent incarceration (Kerr et al., 2007; Pizzicato, Drake, Domer-Shank, Johnson & Viner, 2018), recent period of abstinence (Ahmad et al., 2021; Coffin et al., 2007) and intermittent injecting drug use (Brugal et al., 2002). Use of opioids concomitantly with alcohol or benzodiazepines is common in reported overdoses (Barocas et al., 2019; Darke et al., 2007; Tori, Larochelle & Naimi, 2020) and is associated with an increased risk of overdose compared to opioids alone (Dasgupta et al., 2016; Gudin, Mogali, Jones & Comer, 2014; Macleod et al., 2019; Park, Saitz, Ganoczy, Ilgen & Bohnert, 2015). Concurrent use of opioids and other depressant drugs, not necessarily concomitantly, has also been found to be a marker of increased risk of overdose (Olfson, Wall, Wang, Crystal & Blanco, 2018; Schneider, Park, Allen, Weir & Sherman, 2019, 2020). Existing research has looked beyond the use of individual drugs to understand overdose disparities by classifiying “drug use profiles” using latent class analysis (Schneider et al., 2019; Schneider et al., 2020) and number of drugs used (Ahmad et al., 2021; Alexander et al., 2015). The existing research does not investigate the additive effect of benzodiazepines and alcohol among people who use opioids, and its association with naloxone access and training. The focus on benzodiazepines and alcohol is warranted given the aforementioned risk of overdose when combined with opioids and the high proportion of PWID in Australia who use these drugs (Peacock et al., 2021). Given that non-fatal overdose is a predictor of subsequent overdose (Caudarella et al., 2016; Coffin et al., 2007; Forsyth et al., 2018), understanding the factors associated with non-fatal overdose can help target naloxone provision. Further investigation is needed using a single sample to investigate if the drug use profiles that are associated with non-fatal overdose are also associated with naloxone access and training.

This study firstly aimed to estimate recent non-fatal opioid overdose, access to take-home naloxone, and receipt of naloxone training among people who used opioids or received opioid agonist treatment (OAT) in the preceding six months. This data will explain the extent of the problem and response. Secondly, the study evaluated factors associated with recent non-fatal opioid overdose, access to naloxone, and naloxone training, with a particular focus on drug use profile (concurrent use of opioids, benzodiazepines, and hazardous alcohol use). The findings will provide an overview of factors associated with recent opioid overdose, to understand if they are the same factors associated with naloxone access and training. Finally, the study described naloxone access and training in people reporting recent non-fatal opioid overdose. This will contribute to understanding the gaps in naloxone access among those most at risk of overdose.

Section snippets

Data sources

Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS) Engage is a national observational cohort study of people who have a history of injecting drug use, and report injecting drug use in the preceding six months or are currently receiving OAT (comprising methadone, buprenorphine, and buprenorphine-naloxone in Australia). The study procedures have been described elsewhere (Valerio et al., 2020). Participants were enrolled between 28 May 2018 and 06 September 2019.

Results

ETHOS Engage recruited 1468 participants; 5 (<1%) had insufficient questionnaire data, 16 (1%) withdrew participation, and 4 (<1%) were duplicate enrolments identified across sites, resulting in 1443 participants (98%) eligible for analysis. Of 1443 participants, 163 (11%) were excluded from this analysis as they did not report opioid use or receive OAT in the preceding six months.

In the study population who recently used opioids or received OAT (n = 1280), 35% were female, 62% were aged over

Discussion

In this national study of people who recently used opioids or received OAT in Australia, 7% reported recent opioid overdose, 17% reported ever having naloxone access, and 14% reported ever having naloxone training. Hazardous alcohol use and recent use of benzodiazepines was associated with an increased risk of overdose in people who recently used opioids, compared to people receiving OAT and using no other opioids. While groups at higher risk of non-fatal overdose (e.g. those with recent

Funding

The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS) Engage study is funded by a National Health & Medical Research Council (NHMRC) Partnership project grant (1103165), including funding from New South Wales Health and Cepheid. Cepheid was not involved in the study design, methodology, and writing of this manuscript. The opinions expressed in the paper are those of the authors and do not necessarily represent those of Cepheid. The Kirby Institute is funded by the

Ethical approval

Yes.

Declarations of Interest

AP has received untied educational grant from Seqirus and Mundipharma for study of opioid medications. LD has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma and Seqirus. PR has received speaker fees from Gilead and MSD, and research funding from Gilead. MM has received speaker fees from Abbvie. CT has received speaker fees from Abbvie and Gilead and has received a research grant from Merck outside the submitted

Acknowledgements

The authors thank all participants who took part in the ETHOS Engage study. We first give special acknowledgement to the following peer workers and organisations who helped invaluably with participant recruitment:

The NSW Users and AIDS Association (NUAA): Sara Adey, Rodd Hinton, Melanie Joyce; Youth Link Needle and Syringe Program, Cairns: Astrid Carthew; Hepatitis South Australia: Lisa Carter, Carol Holly; Harm Reduction Western Australia: Lyn Murphy.

We would also like to thank the

References (68)

  • L. Degenhardt et al.

    Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review

    Lancet Global Health

    (2017)
  • J. Grebely et al.

    COVID-19 and the health of people who use drugs: What is and what could be?

    International Journal of Drug Policy

    (2020)
  • T. Kerr et al.

    Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users

    Drug and Alcohol Dependence

    (2007)
  • A. McAuley et al.

    Exploring the life-saving potential of naloxone: A systematic review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users

    International Journal of Drug Policy

    (2015)
  • R.B. Naumann et al.

    Impact of a community-based naloxone distribution program on opioid overdose death rates

    Drug and Alcohol Dependence

    (2019)
  • S.J. Nechuta et al.

    Sociodemographic factors, prescription history and opioid overdose deaths: A statewide analysis using linked PDMP and mortality data

    Drug and Alcohol Dependence

    (2018)
  • M. Olfson et al.

    Risks of fatal opioid overdose during the first year following nonfatal overdose

    Drug and Alcohol Dependence

    (2018)
  • L.N. Pizzicato et al.

    Beyond the walls: Risk factors for overdose mortality following release from the Philadelphia Department of Prisons

    Drug and Alcohol Dependence

    (2018)
  • K.E. Schneider et al.

    Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone

    International Journal of Drug Policy

    (2020)
  • K.E. Schneider et al.

    Patterns of polysubstance use and overdose among people who inject drugs in Baltimore, Maryland: A latent class analysis

    Drug and Alcohol Dependence

    (2019)
  • S. Sherman et al.

    Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city

    Drug and Alcohol Dependence

    (2007)
  • N.J. Ahmad et al.

    Correlates of recent nonfatal overdose among people who inject drugs in West Virginia

    Harm Reduction Journal

    (2021)
  • R.B. Alexander et al.

    High prevalence of non-fatal overdose among people who inject drugs in Malaysia: Correlates of overdose and implications for overdose prevention from a cross-sectional study

    International Journal of Drug Policy

    (2015)
  • Australian Government - Department of Health. (2019). Australian statistical geographical classification–Remoteness...
  • K.A. Bradley et al.

    The AUDIT alcohol consumption questions

    Alcoholism: Clinical & Experimental Research

    (1998)
  • M. Bravo et al.

    The role of repeat training in participants undertaking take home naloxone interventions

    MedRxiv

    (2020)
  • T.M. Brugal et al.

    Factors associated with non-fatal heroin overdose: Assessing the effect of frequency and route of heroin administration

    Addiction

    (2002)
  • M. Buresh et al.

    Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland

    PloS One

    (2020)
  • G.E. Caughey et al.

    Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017

    Medical Journal of Australia

    (2019)
  • K.J. Chronister et al.

    Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program

    Drug and Alcohol Review

    (2018)
  • P.O. Coffin et al.

    Identifying injection drug users at risk of nonfatal overdose

    Academic Emergency Medicine

    (2007)
  • M. Curtis et al.

    Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use

    Harm Reduction Journal

    (2018)
  • S. Darke et al.

    Patterns of nonfatal heroin overdose over a 3-year period: Findings from the australian treatment outcome study

    Journal of Urban Health

    (2007)
  • N. Dasgupta et al.

    Cohort study of the impact of high-dose opioid analgesics on overdose mortality

    Pain Medicine

    (2016)
  • Cited by (4)

    • Perceived availability and carriage of take-home naloxone and factors associated with carriage among people who inject drugs in England, Wales and Northern Ireland

      2022, International Journal of Drug Policy
      Citation Excerpt :

      Yet, findings were less clear with respect to prior engagement with drug treatment programmes. Together, these findings emphasize the importance of ongoing contact with community-based services in enabling naloxone carriage among PWID (Conway et al., 2021; Reed et al., 2019). We found that 39% of PWID included in our study did not carry naloxone, despite reporting very high availability of naloxone (94%).

    • Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

      2021, International Journal of Drug Policy
      Citation Excerpt :

      They identified low naloxone carriage ranges (20-28%) despite moderate naloxone ownership (>50%) among people who use drugs. Similarly, Conway et al., found that among a sample of people who had used opioids or received OAT in the past six months in Australia, only 17% had accessed naloxone in their lifetime and 14% had been trained in how to administer naloxone (Conway et al., 2021). Among a subset (n=91) of people who reported recent overdose, 65% had never received take-home naloxone training or take-home naloxone.

    View full text